Spatial learning and memory impairments are associated with increased neuronal activity in 5XFAD mouse as measured by manganese-enhanced magnetic resonance imaging

Xiang Tang1,*, Di Wu1,*, Li-Hua Gu1, Bin-Bin Nie2, Xin-Yang Qi1, Yan-Juan Wang1, Fang-Fang Wu1, Xiao-Li Li1, Feng Bai1, Xiao-Chun Chen3, Lin Xu4,5, Qing-Guo Ren1 and Zhi-Jun Zhang1

1 Department of Neurology, Affiliated ZhongDa Hospital, Neuropsychiatric Institute, School of Medicine, Southeast University, Nanjing, Jiangsu, China
2 Key Laboratory of Nuclear Analytical Techniques, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China
3 Department of Neurology and Geriatrics, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
4 Key Laboratory of Animal Models and Human Disease Mechanisms, Chinese Academy of Sciences & Yunnan Province, Kunming Institute of Zoology, Kunming, Yunnan, China
5 Graduate School of Chinese Academy of Sciences, Beijing, China

* These authors have contributed equally to this work

Correspondence to: Zhi-Jun Zhang, email: janemengzhang@vip.163.com
Qing-Guo Ren, email: renqingguo1976@163.com

Keywords: Alzheimer’s disease, 5XFAD mice, cognition, neuroimaging, manganese enhanced MRI, Pathology Section

Received: March 25, 2016 Accepted: July 19, 2016 Published: August 17, 2016

ABSTRACT

Dysfunction of neuronal activity is a major and early contributor to cognitive impairment in Alzheimer’s disease (AD). To investigate neuronal activity alterations at early stage of AD, we encompassed behavioral testing and in vivo manganese-enhanced magnetic resonance imaging (MEMRI) in 5XFAD mice at early ages (1-, 2-, 3- and 5-month). The 5XFAD model over-express human amyloid precursor protein (APP) and presenilin 1 (PS1) harboring five familial AD mutations, which have a high APP expression correlating with a high burden and an accelerated accumulation of the 42 amino acid species of amyloid-β. In the Morris water maze, 5XFAD mice showed longer escape latency and poorer memory retention. In the MEMRI, 5XFAD mice showed increased signal intensity in the brain regions involved in spatial cognition, including the entorhinal cortex, the hippocampus, the retrosplenial cortex and the caudate putamen. Of note, the observed alterations in spatial cognition were associated with increased MEMRI signal intensity. These findings indicate that aberrant increased basal neuronal activity may contribute to the spatial cognitive function impairment at early stage of AD, and may further suggest the potential use of MEMRI to predict cognitive impairments. Early intervention that targets aberrant neuronal activity may be crucial to prevent cognitive impairment.

INTRODUCTION

Neuronal activity dysfunction is an important feature of Alzheimer’s disease (AD); such dysfunction typically progresses from early neuronal excitability/hyperactivity to later silencing/hypoactivity [1]. Aberrant increased neuronal activity emerges early in the course of AD [2, 3], as well as in the high-risk population of AD [4-7], which has been considered to be related to cognitive impairment [8, 9]. In vivo blood oxygenation level dependent (BOLD) functional magnetic resonance imaging (fMRI) provides a noninvasive approach for assessing neuronal activity,
the contrast in which is dependent on complex changes in cerebral blood flow (CBF), cerebral blood volume (CBV) and metabolism (oxygen consumption). Subjects with mild cognitive impairment (MCI) show hyperactivation in the medial temporal lobe structures (MTL) [2], parietal and frontal lobes [3] during memory tasks compared with age-matched controls. MCI subjects with early hippocampal hyperactivity exhibit accelerated cognitive decline at later stages of AD [8]. A low dose of the anti-epileptic drug levetiracetam can improve memory performance in MCI subjects by reducing elevated hippocampal activity levels [9]. Asymptomatic offspring of persons with late-onset sporadic AD show more frontal and temporal lobe activation during memory encoding [4]. The high-risk population of AD shows higher activity levels in multiple cognitive brain regions, including the frontal, entorhinal and posterior cingulate cortex (PCC) and the hippocampus, during working memory tasks compared with matched controls. This population includes apolipoprotein E ε4 carriers [5], non-demented carriers of a clusterin (CLU) allele [6] and carriers of the presymptomatic presenilin 1 gene (PS1) mutation [7].

Using different techniques, research has also found that AD transgenic mice show increased neuronal activity at early ages, and inhibition of this increased neuronal activity could rescue cognitive deficits. Double-transgenic APP23 x PS45 mice show a marked increase in the number of hyperactive neurons in the cortex and hippocampus by in vivo 2-photon calcium imaging [10, 11]; in particular, early hyperactivity of hippocampal CA1 neurons is observed prior to the formation of plaque [11]. Electroencephalographic recordings (EEG) in transgenic mice for the human amyloid precursor protein (hAPP) reveal abnormal spike activity in the cortex and hippocampus at an early age [12], suppression of this excitatory neuronal activity can reverse cognitive decline [13]. Aberrant increased neuronal activity may represent an early pathologic event that directly contributes to cognition deficits, or it may represent a compensatory mechanism [14]. However, due to the possible effects of anesthesia and the animal’s physiological conditions on neuronal activity and the hemodynamic response, BOLD fMRI technique is restricted in assessing neuronal activity in small rodents.

Compared to BOLD fMRI, manganese-enhanced magnetic resonance imaging (MEMRI) is an attractive functional neuroimaging technique, which can estimate neuronal activity more directly based on calcium influx at the cellular level, independently of the hemodynamic changes associated to changes in neuronal activity [15]. Divalent ion manganese (Mn2+) presents a high-chemical similarity with calcium (Ca2+), it can enter neurons and other excitable cells during nerve action potentials through calcium pathways, such as voltage-gated calcium channels, N-methyl-D-aspartic acid receptors (NMDAR) and the Na+/Ca2+ exchanger [16]. The administration of the paramagnetic Mn2+ shortens longitudinal (T1) relaxation times of tissues where it has accumulated, resulting in positive contrast enhancement in MRI [17]. The working hypothesis is that the contrast detected with MEMRI is produced by the Mn2+ influx into neurons through calcium channels caused by depolarization. Consequently, brain regions with a high neuronal activity should be characterized by increased signal intensity in a T1-weighted image (T1WI) due to higher Mn2+ accumulation [15].

MEMRI, as a noninvasive approach for mapping neuronal activity, has been successfully used to assess differences in basal brain activity in different animal models such as epilepsy [18], schizophrenia [19], anxiety disorders [20], depression [21], anorexia [22] and alcohol addiction [23]. Furthermore, the change of basal brain activity detected by MEMRI were associated with the emotional and cognitive behavior in these animal models. However, as far as we know, MEMRI has only been applied to study functional brain activity in AD in a few cases. A tauopathy AD mouse model shows reduced basal neuronal activity in the memory formation structures (amygdala and hippocampus) measured by MEMRI at the age when significant neuronal loss and cognitive deficits already exist, while the relationship between brain activity and cognitive behavior in AD mice was unknown [24]. No study has investigated the neuronal activity by MEMRI in the early stage of AD transgenic mice.

Therefore, the main objective of this study was to investigate the neuronal activity alterations by MEMRI and the relationship between spatial cognitive function and neuronal activity in the early ages of a transgenic mouse AD model (5XFAD). Spatial learning and memory impairments are one of the earliest symptoms expressed in AD [25]. We hypothesized that neuronal activity dysfunction occurs early in the AD, and spatial cognitive function impairment is associated with aberrant increased neuronal activity in cognitive brain regions in the early stage of AD. In this study, we tested these hypotheses by addressing the following questions. Did neuronal activity alterations emerge in the early ages of 5XFAD mice? Did neuronal activity alterations become more severe in 5XFAD mice with age? Did neuronal activity alterations associate with spatial cognitive function impairment in the early ages of 5XFAD mice? To test these hypothesis, the present study focused on the early stage by selecting four groups (1, 2, 3 and 5 months of age) of 5XFAD mice [26] compared with age-matched wild-type mice to investigate the following: 1) impairments in spatial learning and memory and their progression with age; 2) region-specific changes in basal neuronal activity in brain regions involved in spatial cognition by high-resolution MEMRI; and 3) the correlation between spatial cognitive function and neuronal activity. (Figure 1)
RESULTS

Comparison of spatial learning and memory of wild-type and 5XFAD mice at four different ages

Figure 2A, 2E, 2I, and 2M shows the animals’ average escape latency onto a hidden platform in acquisition trials of the Morris water maze (MWM) test. The curves for the different groups are similar, with progressively shorter latency on consecutive days. Overall, there was a significant main effect of day on 1, 2, 3, and 5 months old mice and of genotype on 2, 3, and 5 months old mice. The results, analyzed by two-way ANOVA with repeated measures were: day: 1 months old: F(4, 168) = 112.2, p < 0.0001; 2 months old: F(4, 168) = 62.18, p < 0.0001; 3 months old: F(4, 168) = 36.73, p < 0.0001; 5 months old: F(4, 164) = 76.56, p < 0.0001; respectively; genotype: 1 months old: F(1, 42) = 0.8565, p = 0.36; 2 months old: F(1, 42) = 11.77, p = 0.0014; 3 months old: F(1, 42) = 10.10, p = 0.0028; 5 months old: F(1, 41) = 22.05, p < 0.0001; respectively.

On further day-by-day analysis, no statistically

Figure 1: Schematic representation of the experimental timeline and anatomical locations of ROIs. A. Timeline of the MEMRI experiment. After OFT and MWM testing, mice were imaged prior to MnCl₂ injection (Pre-injection) and then injected with MnCl₂ four times separated by 24 h (Inj1-Inj4). Twenty-four hours after the last injection, the mice were imaged again (Post-injection). OFT and MWM testing was repeated on the 12th day after the first injection (Post-Inj12). B.-M. Anatomical locations of ROIs. ROIs were defined manually in multiple slices through each region. Representative slices of ROIs are indicated by the red outlines on the mouse brain atlas (left) and their corresponding MRI T1-weighted images (right), including OB, PFC, MC, SC, CPu, RSC, Tha, Hip, Amy, and ERC.
significant differences from the controls were observed in the training sessions of 1-month-old 5XFAD mice, but 2-, 3- and 5-month-old 5XFAD mice showed significantly prolonged latency of finding the hidden platform compared to controls (Student’s t test. Figure 2E, 2 months old: day 2, \( p = 0.0438, p_c = 0.0729 \); day 3, \( p = 0.0015, p_c = 0.0077 \); day 4, \( p = 0.0353, p_c = 0.0729 \). Figure 2I, 3 months old: day 3, \( p = 0.0030, p_c = 0.0149 \); day 4, \( p = 0.0359, p_c = 0.0630 \); day 5, \( p = 0.0378, p_c = 0.0630 \). Figure 2M, 5 months old: day 3, \( p = 0.0032, p_c = 0.0081 \); day 4, \( p = 0.0079, p_c = 0.0132 \); day 5, \( p = 0.0002, p_c = 0.0012 \), respectively).

Figure 2: Morris water maze (MWM) testing of mice of different ages. A., E., I. and M. Training trials and B.-D., F.-H., J.-L. and N.-P. probe trials of 1-, 2-, 3- and 5-month-old mice, respectively, are shown. The data are presented as the mean ± SEM (\( n = 21-22 \) / group). * \( p < 0.05 \), ** \( p < 0.005 \), *** \( p < 0.0005 \) comparing to age-matched wild-type animals. 1 Mo = 1-month, 2 Mo = 2- month, 3 Mo = 3- month, 5 Mo = 5- month.
In the probe trial, all 5XFAD mice showed a significant decrease in the percentage of time spent in the target quadrant (Student’s t test. Figure 2B, 1 month old, $p = 0.0365$; Figure 2F, 2 months old, $p = 0.0003$; Figure 2J, 3 months old, $p = 0.0161$; Figure 2N, 5 months old, $p = 0.0156$; respectively) and in the number of crossings of the target quadrant (Student’s t test. Figure 2C, 1 month old, $p = 0.004$; Figure 2G, 2 months old, $p = 0.0015$; Figure 2K, 3 months old, $p = 0.0029$; Figure 2O, 5 months old, $p = 0.0124$; respectively). The two genotypes displayed similar swimming speeds at all ages (Student’s t test. $p > 0.05$. Figure 2D, 2H, 2L and 2P).

Comparison of anxiety/depressive-like behavior of wild-type and 5XFAD mice at four different ages

There were no significant differences between 1-, 2-, 3- and 5-month-old wild-type and 5XFAD mice in the behavioral tests (Student’s t test. $p > 0.05$), including the open field test (OFT) (Figure S1), the elevated plus maze (EPM) (Figure S2) and the sucrose preference test (SPT) (Figure S3).

Methodological considerations

In the MEMRI pilot experiment, T1WIs of the same mice before and after systemic MnCl$_2$ injection were obtained. At 24 hours after the last MnCl$_2$ injection, MRI signal contrast enhancement could be observed in multiple brain structures (Figure 3A). Some regions, including olfactory bulb (OB), the hippocampus (Hip) and the pituitary gland (Pit), showed more enhancement. In the coronal view, the layers of the OB were clearly detected, with the glomerular and mitral cell layers showing greater enhancement. The hippocampus was enhanced, with a clear delineation of the CA3 and the dentate gyrus (DG) regions. Pit, an area of the brain that lacks a blood-brain barrier (BBB), showed particularly pronounced enhancement. Voxel-based analysis also showed Mn$^{2+}$-induced signal enhancement was heterogeneous across the brain (Student’s t test. Figure 3B, $p < 0.05$, corrected). Quantitative analysis revealed that the T1WI signal in the regions of interest (ROIs) was significantly enhanced (Paired Student’s t test. OB: $p = 0.0044$, $p_c = 0.0044$; the medial prefrontal cortex (PFC): $p = 0.0023$, $p_c = 0.0034$; the retrosplenial cortex (RSC): $p = 0.0032$, $p_c = 0.0039$; Hip: $p = 0.0012$, $p_c = 0.0024$; the entorhinal cortex (ERC): $p = 0.0007$, $p_c = 0.0021$; Pit: $p < 0.0001$, $p_c = 0.0002$; respectively) following MnCl$_2$ injection (Figure 3C).

No overt motor or other visible disturbances were observed after injection based on the behavioral testing performed prior to Mn$^{2+}$ injection (Student’s t test. $p > 0.05$). On the 12th day after the first injection, there was no significant change in total distance covered (Figure 3D) or speed (Figure 3E) in OFT. Additionally, no significant change was observed in the percentage of time spent in the target quadrant (Figure 3F), crossovers (Figure 3G) or speed (Figure 3H) compared to the probe trial of MWM. In addition, MnCl$_2$ systemic injection did not result in obvious body weight loss in the mice (Figure 3I).

Comparison of MEMRI signal of wild-type and 5XFAD mice after MnCl$_2$ injection at four different ages (ROI analysis)

Similar MR signal enhancement was observed in the formal experiments involving 1-, 2-, 3- and 5-month-old mice of the two strains. Figure 4 shows representative coronal T1WIs of one 5-month-old wild-type and 5XFAD mouse (Figure 4A) after administration of 55.8 mg/kg MnCl$_2$.

Increased signal in the caudate-putamen (CPu) (Student’s t test. Figure 4E, $p = 0.0057$, $p_c = 0.0228$) and in the RSC (Figure 4G, $p = 0.0199$, $p_c = 0.0795$) were observed in 5-month-old 5XFAD mice compared with wild-type controls, but the founding in RSC failed in the FDR correction. Signal in the Hip was significantly increased in 5XFAD mice (Figure 4F, 2 months old, $p = 0.0120$, $p_c = 0.0167$; 3 months old, $p = 0.0107$, $p_c = 0.0167$; 5 months old, $p = 0.0126$, $p_c = 0.0167$, respectively). A consistent increase of signal in the ERC was also observed in 5XFAD mice (Figure 4J, 3 months old, $p = 0.0342$, $p_c = 0.0684$; 5 months old, $p = 0.0191$, $p_c = 0.0684$, respectively), and there was an increased trend in 2-month-old mice ($p = 0.0717$, $p_c = 0.0956$), but all these founding in ERC failed in the FDR correction. There was no significant difference in the signal in the PFC (Figure 4B), motor cortex (MC, Figure 4C), somatosensory cortex (SC, Figure 4D), thalamus (Tha, Figure 4H), amygdala (Amy, Figure 4I) or Pit (Figure 4K) between two strains.

In addition, temporalis muscle did not exhibit significant nonspecific signal enhancements relative to brain tissue after MnCl$_2$ administration. There was no significant difference in the signal intensity in the temporalis muscle between two strains before and after MnCl$_2$ injection at different ages (One-way ANOVA, $p > 0.05$. Figure S4B-S4E).

MnCl$_2$ injection did not result in obvious body weight loss in 1-, 2-, 3- or 5-month-old mice (Two-way ANOVA with repeated measures, $p > 0.05$. Figure 5A, 5E, 5I and 5M). In addition, compared with the behavioral test results obtained prior to Mn$^{2+}$ injection, there was no significant change in total distance (One-way ANOVA, $p > 0.05$. Figure 5B, 5F, 5J and 5N) or speed (Figure 5C, 5G, 5K and 5O) in OFT or in the animals’ speed on the probe trial of MWM (Figure 5D, 5H, 5L and 5P) on the 12th day after the first injection.
Figure 3: Effect of MnCl₂ injection on T1WI and behavior of the mice. A. Coronal T1-weighted images of one representative mouse brain before (A, upper row) and after (A, lower row) MnCl₂ injection. Images are shown with anterior on the left to posterior on the right. Note the pronounced signal enhancement (white arrowhead) in OB, Hip and Pit after injection. B. Increased intensity of T1-weighted MRI signal in mice after (Post) MnCl₂ injection compared with that before (Pre) MnCl₂ injection. Statistical t-maps (thresholded at p < 0.05, corrected) are projected on the standard mouse brain template. C. Quantitative analysis of normalized signal intensity across various ROIs of wild mice before (Pre) and after (Post) MnCl₂ injection. D–I. The OFT, F–H. MWM test and I. body weight of mice before (Pre) and after (Post) MnCl₂ injection. The data are presented as the mean ± SEM (n = 6/group). *p < 0.05, **p < 0.005, ***p < 0.0005, respectively.
The relationship between cognitive behavior and MEMRI signal

In the acquisition trials of the MWM test, there was a significant positive correlation between learning ability (latency to find the platform on day 5) and signal in the Hip (Pearson correlation. Figure 6A, Hip, $r = 0.8668$, $p = 0.0254$, $p_c = 0.038$) of 5-month-old 5XFAD mice. No such correlation was found in Hip of 5XFAD mice 2 or 3 months old.

Figure 4: Manganese enhanced T1WI and quantification of signal in wild-type and 5XFAD mice after MnCl$_2$ injection.

A. Coronal T1WIs of one representative 5-month-old wild-type and 5XFAD mouse after intensity normalization by the temporalis muscle signal after MnCl$_2$ injection. Images are shown with anterior on the left and posterior on the right.

B-K. Quantitative analysis of signal change across various bilateral ROIs of 1-, 2-, 3- and 5-month-old wild and 5XFAD mice after MnCl$_2$ injection. The data are presented as the mean ± SEM ($n = 5-6$ / group). *$p < 0.05$ comparing to age-matched wild-type animals.
months of age or in other ROIs of 5XFAD mice 2, 3 or 5 months of age.

In the probe trial, there was a negative correlation between memory ability (time spent in the target quadrant) and the signal in the ERC of 2-, 3- and 5-month-old 5XFAD mice and in the Hip of 3- and 5-month-old 5XFAD mice (Figure 6B, ERC, 2 months old, \( r = -0.9204, p = 0.0093, p_c = 0.0186 \); Figure 6C, ERC, 3 months old, \( r = -0.8576, p = 0.0290, p_c = 0.058 \); Figure 6E, ERC, 5 months old, \( r = -0.8386, p = 0.0380, p_c = 0.076 \); Figure

**Figure 5:** Effect of MnCl\(_2\) injection on body weight and behavior in the OFT and MWM tests. 1-, 2-, 3- and 5-month-old wild-type and 5XFAD mice were injected with MnCl\(_2\), respectively. A, E, I, and M. The animals’ body weights were recorded during the experiment. B, F, J, and N. Total distance or C, G, K, and O. speed in OFT and D, H, L, and P. speed during the probe trial of MWM were recorded on the 12th day after the first injection (Post-Inj12). The data are presented as the mean ± SEM (\( n = 5-6 / \) group).
6D, Hip, 3 months old, $r = -0.8269, p = 0.0424, p_c = 0.0848$; Figure 6F, Hip 5 months old, $r = -0.8364, p = 0.0380, p_c = 0.0380$; respectively), but the founding in ERC of 3- and 5-month-old mice and in Hip of 3-month-old mice failed in the FDR correction.

No correlation was found between cognitive behavior (in the acquisition trials or in the probe trial) and MEMRI signal within ROIs in the different ages of wide-type mice group.

**DISCUSSION**

The present study demonstrated that spatial cognitive function, especially memory function, is impaired in 5XFAD mice at early ages, and that spatial cognitive function in these animals is negatively correlated with abnormally increased neuronal activity in cognitive brain regions, including the RSC, the Hip, the Cpu and the ERC. To our knowledge, this is the first study to correlate behavior and MEMRI in 5XFAD transgenic mice at early ages.
The 5XFAD mouse model is an early-onset transgenic model that rapidly recapitulates AD amyloid pathology. In these animals, intraneuronal Aβ42 accumulates in the brain starting at 1.5 months; amyloid deposition begins at 2 months, and massive amyloid burden with gliosis and neuronal loss occurs at 9 months of age [26]. Cognitive alterations, including hippocampal-dependent learning and memory impairment [26], frontal-related cognitive deficits [27] and contextual memory deficits [28], have also been described in 5XFAD models. The present study assessed spatial learning and memory function by MWM in 5XFAD mice in the early ages. In this study, male 5XFAD mice showed significant learning impairment at 5 months of age and prolonged escape latency on day 3 at 2 and 3 months of age. In addition, spatial reference memory was impaired in 5XFAD mice at 1 month of age and was sustained to 5 months of age. There was no difference in the swimming speeds of wild-type and 5XFAD mice at any of the ages tested, confirming that the prolonged escape latency and reduced time spent in the target quadrant by 5XFAD mice are not due to reduction of motor activity. Ohno found that 5XFAD mice show impairment in MWM from 4 months of age [29], while Bouter did not find spatial reference memory impairment in MWM in a mixed group of young (3-6 months) mice [30]. Although Kanno found no spatial learning or memory disorders in MWM of 5XFAD mice at 2 months of age (in that study, there was no specification of which gender was used), the study showed that Tau was highly phosphorylated in these animals [31]. Schneider also found no changes in MWM in probe trials of 5XFAD mice at 3 months of age [32], they did not find any difference at 9 months of age either. In the acquisition phase of Schneider’s study, the mice were trained for four days (i.e., 16 trials), whereas we included five days (i.e., 20 trials) of training, a schedule that might offer greater sensitivity for detection of memory impairment. In addition, in our study, 5XFAD mice did not show anxiety/depressive-like behavior in multiple behavioral tests at 1, 2, 3 or 5 months of age, a finding that is also consistent with previous research [32]. In conclusion, our results suggest that spatial cognitive function impairment, especially memory deficit, occurs at an early age in male 5XFAD mice.

MEMRI is an emerging method which can be used to image and estimate neuronal activity in vivo. Mn²⁺ accumulation in neuron due to activation offering an approach to “optically” probe calcium influx in the neuron, which are reflected by corresponding changes in MEMRI signal intensity. The major drawback of using Mn²⁺ as a contrast agent is its cellular toxicity, which may result in acute heart failure or chronic motor dysfunction as well as cognitive dysfunction [33]. Therefore, attempts should be made to increase the sensitivity of MEMRI by optimizing the MRI hardware, MRI sequences, and data analysis to permit use of the lowest possible manganese concentration in vivo.

In order to avoid acute Mn toxicity, the present work applied an optimized MEMRI protocol based on a fractionated Mn²⁺ injection [34] using lower concentrations per injection. During four injection days, no obvious abnormal behaviors, including food intake, water intake and urine or fecal output, were observed. Moreover, no motor dysfunction symptoms of manganism, such as tremor, rigidity, bradykinesia, and clumsiness, were observed. 12 days after the first injection, there was no observable weight loss or motor or cognitive function decrease compared to these behaviors before Mn injection. Therefore, it may suggest that the toxicity effects caused by Mn injection, including neurotoxicity, to the findings in this study may be negligible. In addition, fractionated application achieved a cumulative concentration of manganese sufficient for functional mapping. Resolution of specific layers in the OB and clear delineation of the CA3 and DG in the hippocampus were obtained. Image enhancement was most clearly visible in Pit, which lacks a BBB and therefore has easy access to Mn²⁺ in the blood.

To overcome problems associated with the comparison of quantitative assessments from different individuals, normalization of signal intensity [35] by choosing a presumably unaffected region is a common procedure [36-38]. In this study, the temporalis muscle of each animal was chosen to serve as a reference for signal normalization and it did not exhibit significant nonspecific signal enhancements or unexpected differences in this administered dose. Furthermore, in order to avoid various factors including regional differences of radio frequency (RF) coil sensitivity and baseline tissue T1 relaxation differences, the data was presented by the muscle normalized T1WI signals of each area after MnCl₂ administration corresponding to the muscle normalized T1WI signals in the same area before MnCl₂ administration. Through this process, the signal enhancement following MnCl₂ administration can be independent of the RF coil sensitivity profile. Overall, our results indicate that the dose of MnCl₂, the MRI sequences and the data analysis methods used in this study are sufficiently sensitive to detect functional neuronal changes in the studied animals.

For MEMRI, anesthesia is only necessary during MRI imaging; thus, it can yield maps of accumulated neuronal activity from awake and behaving animals. The present study applied in vivo MEMRI to the study of basal levels of neuronal activity in normally-behaving 5XFAD mice. The mice were injected with MnCl₂ during 4 days under normal behavioral conditions with free access to food and water, so we interpreted the functional MEMRI results as representing basal neuronal activity during four-day period of the manganese phase under baseline, non-stimulated conditions. We performed anatomical ROI analyses of brain regions selected on the basis of their...
hypothesized involvement in spatial cognitive circuits and other cortical or sub-cortical structures as controls. In 5XFAD mice, neuronal activity was increased in the Hip and ERC at age 2 months, and this increase was sustained to 5 months of age, although the founding in ERC failed in the FDR correction. Neuronal activity was also increased in the RSC and CPu of these animals at 5 months of age while the founding in RSC failed in the FDR correction. A large body of evidence has implicated the role of MTL structures, particularly the Hip and ERC, in memory formation. Furthermore, the Hip and ERC are the regions that show the earliest vulnerability to AD pathogenesis [39]. The PCC / RSC, which encodes and stores spatial information [40], has a very different role in spatial memory from that of the Hip and the anterior thalamic nuclei [41]. Caudate-putamen (CPu) is also involved in learning [42] and spatial memory [43]. As previously mentioned, increased neuronal activity in the MTL and RSC has been found not only at early stages of AD in humans but also in several AD mouse models, and reversing this abnormally increased neuronal activity can reverse learning and memory deficits [9, 13, 44]. Furthermore, an apparent symptom of altered neuronal activity in the early stages of AD is an increased frequency of epileptic seizures, which is observed both in human patients [45] and in mouse models. Intriguingly, epileptic activity also appeared to be associated with an earlier onset of cognitive decline [46]. Consistent with these previous studies, the present study found a negative correlation between increased basal neuronal activity in these spatial cognitive structures (but may not limited to) and spatial cognitive performance in MWM, suggesting a relationship between increased neuronal activity and decreased spatial learning and memory function. Our findings in these 5XFAD mice add further support the hypothesis that aberrant increased neuronal activity in cognitive brain regions may contribute to cognitive impairment in the early stage of AD [47]. These results also highlight the potential usefulness of MEMRI for measuring neuronal activity in the context of aging and neuropsychiatric disorders and suggest that MEMRI signal intensity may serve as a marker for predicting cognitive deficits.

The mechanism of increased neuronal activity in the early stage of AD is unclear. One hypothesis is that the increased activity may represent a compensatory response [14, 48] occurs as cognition begins to be impaired by AD-related neuropathological changes such as Aβ deposition. Other studies suggest a pathogenic mechanism in which the primary neuronal dysfunction reflects ongoing damage, is harmful, and may be associated with a higher rate of disease progression.

The present study has several limitations. First, AD is an age-related illness, whereas the 5XFAD mouse model recapitulates AD pathology during development. The influence of the possible abnormal brain development on the neuronal activity in the early ages could not be completely excluded. Second, the 5XFAD mouse model only involved AD amyloid pathology while various pathophysiology mechanisms are involved in AD. Whether neuronal activity alterations in the early ages is a common problem of AD need to be confirmed by other types of AD transgenic mice models, such as tauopathy AD mouse model and triple-transgenic AD (3xTg-AD) mice. Third, in addition to assessing active neurons, MEMRI enhancement may also be partly related to the presence of reactive astrocytes [49] or activated microglia. Studies have confirmed that these cells have also involved in brain neural activity. Fourth, T1 mapping may be another sensitive method which takes longer imaging time to assess neuronal activity in MEMRI. We can use both two methods (T1WI and T1 mapping) to better understand the change of Mn²⁺ uptake and accumulation in MEMRI in the future study. Fifth, this study has found early neuronal activity alterations, long-term follow up study may further increase our understanding of neuronal activity alterations during the disease progression. Finally, the sample size is relatively small to correlate behavioral variables and MEMRI signals. Thus, we must be careful to draw conclusions. We should increase sample size in the future research to further confirm these initial findings.

Combining MEMRI and behavioral tests makes it possible to explore the relationship between neuronal activity and cognitive dysfunction in animal models. Collectively, these findings add to our understanding of the potential usefulness of MEMRI to predict cognitive impairments, and how early interventions could be used to target aberrant neuronal activity in a way that may be crucial in preventing cognitive deficits in AD.

**MATERIALS AND METHODS**

**Ethics statement**

Investigation has been conducted in accordance with the ethical standards and according to the Declaration of Helsinki and according to national and international guidelines and has been approved by the Animal Care and Use Committee of Southeast University (Nanjing, Jiangsu, China). All experimental methods were carried out in accordance with the approved guidelines.

**Animals**

5XFAD mice, which were developed by Oakley et al. [26], co-express human APP and presenilin 1 with five familial AD mutations (APP K670N/M671L + I716V + V717I and PS1 M146L + L286V). These mice were gifts from Prof. Xiaochun Chen (Department of Fujian Medical University, Fuzhou, China). Mice were generated and maintained in the C57BL/6 background.
Genotyping was performed by polymerase chain reaction analysis of tail DNA. Male 5XFAD mice and age-matched C57BL/6J wild mice were used in the experiments. All the mice were identically housed in a temperature and humidity-controlled vivarium on a 12-h dark/light cycle with free access to food and water. The experiments were performed with animals 1, 2, 3 and 5 months of age by experimenters who were blinded with respect to the animals’ genotypes. All protocols and procedures used in the study were approved by the Jiang Su Animal Care and Use Committee.

Behavioral tests

The order of the behavior tests was as follows: OFT, EPM, SPT and MWM. The methods to perform the OFT, EPM and SPT were provided in the supplementary information.

Morris water maze (MWM)

The maze consisted of a white circular pool (122 cm in diameter and 51 cm in height) filled with water (20 ± 2°C) that was made opaque by a white nontoxic pigment. The pool was divided into four quadrants: northwest (NW), northeast (NE), southeast (SE) and southwest (SW). A platform (9 cm in diameter) that was not visible from the water surface was positioned 1 cm below the water surface in the one of the quadrants (NW). The experiment consisted of two phases including consecutive acquisition trials and one probe trial. Briefly, the acquisition trials comprised four trials per day over a period of 5 days with an inter-trial interval of 20 min. In the four daily trials, each of which began at a different position in the pool, the mouse was allowed to swim for 60 s; if the mouse failed to find the platform, it was guided onto the platform and allowed to remain on it for 15 s. Spatial memory was assessed in a 60-s probe trial on day 6 during which the platform was removed from the pool. An automatic tracking system was used to record the time required to find the platform (escape latency) in the acquisition trials, the animal’s swimming speed, the time spent in the target quadrant and crossovers in the target quadrant in the probe trial. All animals (n = 21-22 / group) were tested in MWM.

Manganese administration and MRI

An MEMRI pilot experiment was first conducted to test the chosen dose of Mn^{2+} and MRI sequence based on previous studies [15]. After behavioral testing, adult C57BL/6 wild mice (male, 8 weeks of age, n = 6) were imaged prior to MnCl\textsubscript{2} injection to acquire T1WI in a baseline scan; the mice were then injected with manganese chloride (MnCl\textsubscript{2}.4H\textsubscript{2}O, Bio Basic Inc., Canada) dissolved in bicine (di(hydroxyethyl)glycine, Sigma-Ulrich, UK) buffer pH 7.4. To reduce acute peripheral Mn^{2+} overexposure, a total dose of 55.8 mg/kg MnCl\textsubscript{2}.4H\textsubscript{2}O (i.e., 279 μmol/kg) was injected intraperitoneally (i.p.) in four fractionated doses of 13.95 mg/kg with an inter-injection interval of 24 hours. The mice were returned to their home cages under normal behavioral conditions with free access to food and water, and imaged again 24 hours after the last injection to measure the level of Mn^{2+} uptake in the brain. On the 12th day after the first injection (Post-Inj12), OFT and MWM were repeated to assess the effect of MnCl\textsubscript{2} injection on the animals’ behavioral functions (Figure 1A).

In the formal experiments involving 1-, 2-, 3- and 5-month-old mice, after behavioral testing, some mice were randomly assigned to the MEMRI experimental group (n = 6 / group), the remaining mice were randomly assigned to the other experimental group (unpublished data). The procedure of the formal MEMRI experiment was the same as MEMRI pilot experiment (Figure 1A). These mice were checked daily, including an inspection of the injection site, and their behavior and weight were monitored.

Experiments were performed on a 7.0 Tesla small-animal magnetic resonance system (PharmaScan, Bruker, Germany) using a 72-mm transmit-only RF coil and a receive-only quadrature surface coil. Isoflurane (3.5% for induction and approximately 1.5% for maintenance) was used for anesthesia. Breathing frequency and body temperature were monitored, and temperature was maintained within physiological limits using an animal warming system (MT1025, Bruker Biospin, Germany). A T1WI scan was acquired using rapid acquisition with relaxation-enhancement (RARE) pulse sequence with the following parameters: Rare factor = 4, echo spacing = 9.0 ms, field of view (FOV) = 24.4 mm x 24.4 mm, matrix size = 384 x 384, repetition time (TR) = 1430 ms, echo time (TE) = 8.89 ms, slice thickness = 0.5 mm, slices = 30 (axial view), number of excitation (NEX) = 8, acquisition time = 13 min 43 sec.

MR image processing

Images were reconstructed using Paravision software 5 (Bruker BioSpin, Germany) and transferred to a standard ANALYZE format. Voxel-based analysis was implemented with Matlab (version R2010b, The MathWorks Inc., Natick, MA, USA) through Statistical Parametric Mapping (SPM8, http://www.fil.ion.ucl.ac.uk/spm), and SPM-Mouse (http://www.wbic.cam.ac.uk/~sjs80/spmmouse.html). Briefly, after being spatially pre-processed and cropped, T1-weighted images were spatially normalized to a standard mouse brain template [50] using a structural image unified segmentation approach. Voxel-wise independent Student’s t-test between two time points (before and
after MnCl₂ injection) was performed in SPM8. Results were thresholded at a p level of < 0.05, corrected by the AlphaSim program based on a Monte Carlo simulation. ROIs were drawn manually on each individual’s T1wI according to the mouse brain atlas (Figure 1B) [51] by Mricron (http://www.mccauslandcenter.sc.edu/mricro/mricron/install.html). These ROIs included the major areas in the OB (bregma 4.28 to 3.56 mm), PFC (bregma 2.96 to 0.14 mm), MC (bregma 0.14 to 2.46 mm), SC (bregma 1.94 to -1.94 mm), CPu (bregma 1.42 to -0.82 mm), Hip (bregma -1.06 to -3.80 mm), Tha (bregma -1.22 to -2.54 mm), RSC (bregma -1.06 to -4.16 mm), Amy (bregma -0.94 to -2.46 mm) and ERC (bregma -2.92 to -3.72 mm) (Figure 1B-1M). The Pit was also selected as controls to evaluate nonspecific enhancement. All MEMRI data were checked by at least two independent experimenters who were unaware of the experimental conditions. The mean signal intensity (SI) of all voxels in the respective ROIs, averaged for both hemispheres, was calculated. Signal normalization was performed by dividing the mean SI within ROIs by the mean SI in the temporalis muscle (Figure S4) of the same mouse (normalized ROI SI = ROI SI/muscle SI). In other words, SIs within the ROIs were normalized SI, except for muscle SI data which are reported as raw values. Normalized ROI SI was calculated before (S0, in baseline scan) and after MnCl₂ injection (S1) in the same mouse, and signal change due to Mn²⁺-induced enhancement was calculated as: 100% × (S1 - S0)/S0.

**Statistical analysis**

Data were analyzed using SPSS 20.0 software (SPSS, Inc., Chicago, IL, USA) and R 3.3.0 (https://www.r-project.org/); values are presented as the means ± standard error (S.E.M). Data from acquisition trials of MWM and body weight were analyzed by two-way repeated measures analysis of variance (ANOVA) with two factors, groups (5XFAD, wild) and time (day). Other collected data from the MWM probe trials, OFT, EPM, SPT and MRI experiments were analyzed by Student’s t-test between two groups or one-way ANOVA among four groups. Pearson correlation (two-tailed) was conducted to analyze the relationships between cognitive behavior (latency to find the platform on day 5 and time spent in the target quadrant) and MEMRI signal intensity within the ROI. The significance level was set at p < 0.05. To control for multiple testing correction, the false discovery rate (FDR) was used for correction [52, 53] and statistical significance was defined for FDR-corrected p< 0.05.

**CONFLICTS OF INTEREST**

The authors declare that they have no conflict of interest.

**GRANT SUPPORT**

This work was supported in part by grants from the National Natural Science Foundation of China (91232707, 81420108012, and Zhi-jun Zhang), the National Major Science and Technology Program of China (No. 2012ZX09506-001-009, Zhi-Jun Zhang), the Key Program for Clinical Medicine and Science and Technology, Jiangsu Provincial Clinical Medical Research Center (BL2013025), National High-tech R&D Program (863 Program) (No.2015AA020508), National Basic Research Program of China (2013CB835103) and Strategic Priority Research Program of Chinese Academy of Science (XDB2020002).

**REFERENCES**

1. Palop JJ and Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci. 2010; 13:812-818.
2. Terry DP, Sabatinelli D, Puente AN, Lazar NA and Miller LS. A Meta-Analysis of fMRI Activation Differences during Episodic Memory in Alzheimer’s Disease and Mild Cognitive Impairment. Journal of neuroimaging. 2015.
3. Bokde AL, Karmann M, Born C, Teipel SJ, Omerovic M, Ewers M, Frodl T, Meisenzahl E, Reiser M, Moller HJ and Hampel H. Altered brain activation during a verbal working memory task in subjects with amnestic mild cognitive impairment. J Alzheimers Dis. 2010; 21:103-118.
4. Bassett SS, Yousem DM, Cristinizio C, Kusevic I, Yassa MA, Caffo BS and Zeger SL. Familial risk for Alzheimer’s disease alters fMRI activation patterns. Brain. 2006; 129:1229-1239.
5. Bookheimer S and Burggren A. APOE-4 genotype and neurophysiological vulnerability to Alzheimer’s and cognitive aging. Annual review of clinical psychology. 2009; 5:343-362.
6. Lancaster TM, Baird A, Wolf C, Jackson MC, Johnston SJ, Donev R, Thome J and Linden DE. Neural hyperactivation in carriers of the Alzheimer’s risk variant on the clusterin gene. European neuropsychopharmacology. 2011; 21:880-884.
7. Quiroz YT, Budson AE, Celone K, Ruiz A, Newmark R, Castrillon G, Lopera F and Stern CE. Hippocampal hyperactivation in presymptomatic familial Alzheimer’s disease. Ann Neurol. 2010; 68:865-875.
8. Miller SL, Fenstermacher E, Bates J, Blacker D, Sperling RA and Dickerson BC. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. Journal of neurology, neurosurgery, and psychiatry. 2008; 79:630-635.
9. Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, Yassa MA, Bassett SS, Shelton AL and Gallagher M. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron.
10. Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haas C, Staufenbiel M, Konnerth A and Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer’s disease. Science. 2008; 321:1686-1689.

11. Busche MA, Chen X, Henning HA, Reichwald J, Staufenbiel M, Sakmann B and Konnerth A. Critical role of soluble amyloid-beta for early hippocampal hyperactivity in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2012; 109:8740-8745.

12. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL and Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease. Neuron. 2007; 55:697-711.

13. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ and Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc Natl Acad Sci U S A. 2012; 109:E2895-2903.

14. Huijbers W, Mormino EC, Schultz AP, Wigman S, Ward AM, Larvie M, Amargilio RE, Marshall GA, Rentz DM, Johnson KA and Sperling RA. Amyloid-beta deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain. 2015; 138:1023-1035.

15. Massaad CA and Pautler RG. Manganese-enhanced magnetic resonance imaging (MEMRI). Methods Mol Biol. 2011; 711:145-174.

16. Takeda A. Manganese action in brain function. Brain research Brain research reviews. 2003; 41:79-87.

17. Silva AC, Lee JH, Aoki I and Koretsky AP. Manganese-enhanced magnetic resonance imaging (MEMRI): methodological and practical considerations. NMR in biomedicine. 2004; 17:532-543.

18. Angenstein F, Niessen HG, Goldejschmidt J, Lison H, Altrock WD, Gundelfinger ED and Scheich H. Manganese-enhanced MRI reveals structural and functional changes in the cortex of Bassoon mutant mice. Cereb Cortex. 2007; 17:28-36.

19. Lutkenhoff E, Karlsgodt KH, Gutman B, Stein JL, Thompson PM, Cannon TD and Jentsch JD. Structural and functional neuroimaging phenotypes in dysbindin mutant mice. Neuroimage. 2012; 62:120-129.

20. McGuire JL, Bergstrom HC, Parker CC, Le T, Morgan M, Tang H, Selwyn RG, Silva AC, Choi K, Ursano RJ, Palmer AA and Johnson LR. Traits of fear resistance and susceptibility in an advanced intercross line. Eur J Neurosci. 2013; 38:3314-3324.

21. Knapman A, Kaltwasser SF, Martins-de-Souza D, Holsboer F, Landgraf R, Turk C, Czisch M and Touma C. Increased stress reactivity is associated with reduced hippocampal activity and neuronal integrity along with changes in energy metabolism. Eur J Neurosci. 2012; 35:412-422.

22. Just N and Gruetter R. Detection of neuronal activity and metabolism in a model of dehydration-induced anorexia in rats at 14.1 T using manganese-enhanced MRI and 1H MRS. NMR in biomedicine. 2011; 24:1326-1336.

23. Dudek M, Abo-Ramadan U, Hermann D, Brown M, Canals S, Sommer WH and Hyytia P. Brain activation induced by voluntary alcohol and saccharin drinking in rats assessed with manganese-enhanced magnetic resonance imaging. Addiction biology. 2014.

24. Perez PD, Hall G, Kimura T, Ren Y, Bailey RM, Lewis J, Febo M and Sahara N. In vivo functional brain mapping in a conditional mouse model of human tauopathy (taup301l) reveals reduced neural activity in memory formation structures. Mol Neurodegener. 2013; 8:9.

25. Tromp D, Dufour A, Lithfous S, Pebayle T and Despres O. Episodic memory in normal aging and Alzheimer disease: Insights from imaging and behavioral studies. Ageing Res Rev. 2015; 24:232-262.

26. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R and Vassar R. Infraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006; 26:10129-10140.

27. Girard SD, Baranger K, Gauthier C, Jacquet M, Bernard A, Escoffier G, Marchetti E, Khrestchatisky M, Rivera S and Roman FS. Evidence for early cognitive impairment related to frontal cortex in the 5XFAD mouse model of Alzheimer’s disease. J Alzheimer’s Dis. 2013; 33:781-796.

28. Kaczorowski CC, Sametksy E, Shah S, Vassar R and Disterhoft JF. Mechanisms underlying basal and learning-related intrinsic excitability in a mouse model of Alzheimer’s disease. Neurobiol Aging. 2011; 32:1452-1465.

29. Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R and Disterhoft JF. Temporal memory deficits in Alzheimer’s mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci. 2006; 23:251-260.

30. Bouter Y, Kacprowski T, Weissmann R, Dietrich K, Borgers H, Braus A, Sperling C, Wirths O, Albrecht M, Jensen LR, Kuss AW and Bayer TA. Deciphering the molecular profile of plaques, memory decline and neuron loss in two mouse models for Alzheimer’s disease by deep sequencing. Front Aging Neurosci. 2014; 6:75.

31. Kanno T, Tsuchiya A and Nishizaki T. Hyperphosphorylation of Tau at Ser396 occurs in the much earlier stage than appearance of learning and memory disorders in 5XFAD mice. Behav Brain Res. 2014; 274:302-306.
32. Schneider F, Baldauf K, Wetzel W and Reymann KG. Behavioral and EEG changes in male 5xFAD mice. Physiol Behav. 2014; 135:25-33.

33. Aschner M, Guilarte TR, Schneider JS and Zheng W. Manganese: recent advances in understanding its transport and neurotoxicity. Toxicol Appl Pharmacol. 2007; 221:131-147.

34. Grunecker B, Kaltwasser SF, Zappe AC, Bedenk BT, Bicker Y, Spoormaker VI, Wotjak CT and Czisch M. Regional specificity of manganese accumulation and clearance in the mouse brain: implications for manganese-enhanced MRI. NMR in biomedicine. 2013; 26:542-556.

35. Cross DJ, Minoshima S, Anzai Y, Flexman JA, Keogh BP, Kim Y and Maravilla KR. Statistical mapping of functional olfactory connections of the rat brain in vivo. Neuroimage. 2004; 23:1326-1335.

36. Lindsey JD, Scadeng M, Dubowitz DJ, Crowston JG and Weinreb RN. Magnetic resonance imaging of the visual system in vivo: transsynaptic illumination of V1 and V2 visual cortex. Neuroimage. 2007; 34:1619-1626.

37. Smith KD, Kallhoff V, Zheng H and Pautler RG. in vivo axonal transport rates decrease in a mouse model of Alzheimer's disease. Neuroimage. 2007; 35:1401-1408.

38. Weng JC, Chen JH, Yang PF and Tseng WY. Functional mapping of rat barrel activation following whisker stimulation using activity-induced manganese-dependent contrast. Neuroimage. 2007; 36:1179-1186.

39. Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN, Dale AM, Stern CE, Blacker D, Albert MS and Sperling RA. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol. 2004; 56:27-35.

40. Czajkowski R, Jayaprakash B, Wiltgen B, Rogerson T, Guzman-Karlsson MC, Barth AL, Trachtenberg JT and Silva AJ. Encoding and storage of spatial information in the retrosplenial cortex. Proc Natl Acad Sci U S A. 2014; 111:8661-8666.

41. Nelson AJ, Powell AL, Holmes JD, Vann SD and Aggleton JP. What does spatial alternation tell us about retrosplenial cortex function? Front Behav Neurosci. 2015; 9:126.

42. Mattfeld AT, Gluck MA and Stark CE. Functional specialization within the striatum along both the dorsal/ventral and anterior/posterior axes during associative learning via reward and punishment. Learn Mem. 2011; 18:703-711.

43. Xu H, Yang HJ and Rose GM. Chronic haloperidol-induced spatial memory deficits accompany the upregulation of D(1) and D(2) receptors in the caudate putamen of C57BL/6 mouse. Life Sci. 2012; 91:322-328.

44. Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I, Mucke L and Palop JJ. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell. 2012; 149:708-721.

45. Palop JJ and Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Archives of neurology. 2009; 66:435-440.

46. Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, Hegde M, Cornes SB, Henry ML, Nelson AB, Seeley WW, Geschwind MD, Gorno-Tempini ML, et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA neurology. 2013; 70:1158-1166.

47. Busche MA and Konnerth A. Neuronal hyperactivity—A key defect in Alzheimer’s disease? BioEssays. 2015; 37:624-632.

48. Hamalainen A, Phlajamaki M, Tanila H, Hanninen T, Niskanen E, Tervo S, Karjalainen PA, Vanninen RL and Soininen H. Increased fMRI responses during encoding in mild cognitive impairment. Neurobiol Aging. 2007; 28:1889-1903.

49. Silva AC and Bock NA. Manganese-enhanced MRI: an exceptional tool in translational neuroimaging. Schizophr Bull. 2008; 34:595-604.

50. Sawiak SJ, Wood NI, Williams GB, Morton AJ and Carpenter TA. Voxel-based morphometry in the R6/2 transgenic mouse reveals differences between genotypes not seen with manual 2D morphometry. Neurobiol Dis. 2009; 33:20-27.

51. Paxinos G. & Franklin, K.B.J. The mouse brain in stereotaxic coordinates: second edition. [51-124] (Academic Press, New York, 2001)

52. Hochberg Y and Benjamini Y. More powerful procedures for multiple significance testing. Statistics in medicine. 1990; 9:811-818.

53. Yin RH, Li J, Tan L, Wang HF, Tan MS, Yu WJ, Tan CC, Yu JT, Tan L and Alzheimer’s Disease Neuroimaging I. Impact of SORL1 genetic variations on MRI markers in non-demented elders. Oncotarget. 2016; doi: 10.18632/oncotarget.9300.